MALE DIABETIC SEXUAL IMPOTENCE - EFFECTS OF DOPAMINERGIC AGENTS

A double blind study was carried out with placebo and dopaminergic agents in 100 patients with male diabetic sexual impotence. In basal conditions, mean serum follitropin, lutropin, PRL [prolactin], and testosterone levels did not significantly differ from those found in a normal control group. No significant variations with the exception of PRL reduction were observed after use of the dopaminergic agents. Sexual activity was improved in 50% of cases after 3,4-dihydroxyphenylalanine and 10% of those of the placebo group. In patients treated with bromocriptine, 20% improved their sexual function without changes in those receiving placebo.